Article information
Cualquier actividad humana carga con la posibilidad de provocar un error. Un espíritu crítico respecto a este patrimonio exclusivo de los hombres es la mejor garantía para no perseverar en el mismo; otra actitud sería aparentemente impropia de nuestra especie por simple irracionalidad.
En medicina y en relación con el tratamiento de la tuberculosis, la yatrogenia puede tener características dramáticas por sus trágicos resultados. Teóricamente es importante diferenciar estas dos situaciones: 1. Yatrogenia inevitable pero corregible, secundaria a los efectos adversos de cada droga, frecuentemente no bien conocidos. 2. Yatrogenia evitable e inexcusable, propia del uso incorrecto de los recursos terapéuticos por parte del médico.
La revisión de estos aspectos con la intención de aclarar algunas dudas y de crear inquietud son los únicos objetivos del presente trabajo, para contribuir a la aún lejana eliminación de esta enfermedad de nuestro medio. Todo médico conoce que es perfectamente curable y en muchos casos inevitable.
Any human activity assumes the responsability of the possibility to cause an error. A critical spirit concerning this exclusive patrimony of men is the best guarantee in order to don’t persevere in the same; other attitude would be apparently inappropriate of our species for irrationality.
In medicine and in relationship with the tuberculosis treatment the iatrogenia could have dramatic characteristics for their tragic results. Is important distinguish these two situations: 1. Inevitable iatrogenia but recoverable, secondary to the adverse effects of every drugs frequently no very well-known. 2. Avoidable iatrogenia and inexcusable, because the incorrect use of the therapeutics facilities per party of the doctor.
The revision of these aspects with the intention of becoming clear some doubts and of creating certain anxiety is the only goals of the current paper and always with the purpose of contributing to the still distant elimination of this illness of our medium. All physician knows that it is perfectly curable and avoidable in many cases.
Full text is only aviable in PDF
Bibliografía
[1.]
Medical Research Council Tuberculosis, Chest Disease Unit.
Treatment of pulmonary tuberculosis in patients notified in England and Wales in 1978-9. Chemotherapy and hospital admission.
Thorax, 40 (1985), pp. 113-120
[2.]
British Medical Research Council.
Cooperative controlled trial of a standard regimen of streptomycin. PAS and isoniazid and three alternative regimens of chemotherapy in Britain.
Tubercle, 54 (1973), pp. 99-129
[3.]
A.B. Miller, A.J. Nunn, D.K. Robinson, G.C. Ferguson, W. Fox, R. Tall.
A second international cooperative investigation into thiacetazone side-effects. 1-The influence of a vitamin and antihistamine supplement.
Bull World Hlth Org, 43 (1970), pp. 107-125
[4.]
B.S. Bomb, S.D. Purohit, H.K. Bedi.
Stevens-Johnson sindrome caused by isoniazid.
Tubercle, 57 (1976), pp. 229-230
[5.]
S.K. Sarkar, S.D. Purohit, T.N. Sharma, M.P. Chawla, D.N. Gupta.
Stevens-Johnson sindrome caused by streptomycin.
Tubercle, 63 (1982), pp. 137-138
[6.]
D.J. Girling.
Adverse cffects of antituberculosis drugs.
Drugs, (1982), pp. 56-74
[7.]
C.L. Holland, C. Malasky, A. Ogunkoya, L. Bielory.
Rapid oral desensitization to isoniazid and rifampicin.
Chest, 98 (1990), pp. 1.518-1.519
[8.]
M.W. Long, D.E. Snider, L. Farer.
Public Health Service Cooperative Trial of three rifampicin-isoniazid regimens in the treatment of pulmonary tuberculosis.
Am Rev Respir Dis, 119 (1979), pp. 879-894
[9.]
L.B. Reichman, R.J. McDonald.
Tratamiento práctico y control de la tuberculosis. Enfermedades pulmonares.
Clin Med N Am, 1 (1977), pp. 1.185-1.204
[10.]
F.S. Cross, M.W. Long, A.S. Banner, D.E. Snider.
Rifampicinisoniazid therapy of alcoholic and non alcoholoic tuberculous patients in a US public Health Service Cooperative Therapy Trial.
Am Rev Respir Dis, 122 (1980), pp. 349-353
[11.]
J.R. Mitchell, H.J. Zimmerman, K.G. Ishak, et al.
Isoniazid liver injury: Clinical spectrum, pathology, and probable pathogcnesis.
Ann Intern Med, 84 (1976), pp. 181-192
[12.]
C. Gronhagen-Riska, P.E. Hellstrom, B. Froseth.
Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis.
Am Rev Respir Dis, 118 (1978), pp. 461-466
[13.]
Modern Drug Treatment of Tuberculosis.
Horne NW. The Chest, Heart and Stroke Association, (1990),
[14.]
R.A. Garibaldi, R.E. Drusin, S.H. Ferebee, M.B. Gregg.
Isoniazidassociated hepatitis: report of an outbreak.
Am Rev Respir Dis, 106 (1972), pp. 357-365
[15.]
N. Riska.
Hepatitis cases in isoniazid treated groups and in a control group.
Bull Int Un Tuberc, 51 (1976), pp. 203-208
[16.]
D.N. Rose, C.B. Schechter, A.I. Silver.
The age threshold for isoniazid chemoprofilaxis: a decision analysis for low risk tuberculin reactors.
JAMA, 256 (1986), pp. 2.709-2.713
[17.]
G.W. Comstock.
Prevention of tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks.
JAMA, 256 (1986), pp. 2.729-2.730
[18.]
S.P. Triphaty.
A slow release preparation of isoniazid. Therapeutic efficacy and adverse side effects.
Bull Int Un Tuberc, 51 (1976), pp. 133-141
[20.]
B.J. Girling.
La hepatitis y otras reacciones secundarias de la quimioterapia antituberculosa.
Bol Un Int Tuberc, 55 (1980), pp. 93-101
[21.]
A. Malcom, et al.
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
Chest, 99 (1991), pp. 465
[22.]
D.J. Girling.
The hepatic toxicity of antituberculosis regimens containing isoniazid. rifampin and pyrazinamide.
Tubercle, 59 (1978), pp. 13-32
[23.]
H.M. McLeod, D. Hay, S.M. Stewart.
The use of pyrazinamide plus isoniazid in the treatment of pulmonary tuberculosis.
Tubercle, 40 (1959), pp. 14-20
[24.]
D.J. Girling.
Adverse reactions to rifampicin in antituberculosis regimens.
J Antimicrobiol Chemother, 3 (1977), pp. 115-132
[25.]
M. Aquinas, W.G.L. Alian, P.A.L. Horsfall, et al.
Adverse reaction to daily and intermittent rifamicin regimens for pulmonary tuberculosis in Hong Kong.
Br Med J, 1 (1972), pp. 765-771
[26.]
F.J. Guerra, R. Rey.
Intolerancias en el curso de un tratamiento controlado con rifampicina y etambutol.
Symposium Mediterráneo de Tisiología, (1973),
[27.]
A.K. Dutt, L. Jones, W.W. Stead.
Short course chemotherapy for tuberculosis with largely twice weekly isoniazid and rifampicin.
Chest, 75 (1979), pp. 441-447
[28.]
F.J. Guerra Sanz.
Side effects during intermittent rifampicin and ethambutol treatment. A preliminary report.
Sean J Respir Dis, 84S (1973), pp. 160-165
[30.]
Singapore Tuberculosis Service/British Medical Research Council.
Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore.
Am Rev Respir Dis, 116 (1977), pp. 807-820
[31.]
M. Zierski, E. Bek.
Side effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study.
Tubercle, 61 (1980), pp. 41-49
[32.]
Hong Kong Tuberculosis Treatment Services/Bromptom Hospital/British Medical Research Council.
A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: Results up to 30 months.
Tubercle, 56 (1975), pp. 179-189
[33.]
R. Nessi, E. Domenichini, G. Fowstem.
«Allergic» reactions during rifampicin treatment: a review of published cases.
Scand J Respir Dis, 84S (1973), pp. 15
[34.]
H. Schubotte, S. Weber.
Rifampicin-dependent reactions against erythrocytes in the sera of patients receiving rifampicin therapy.
Scand J Respir Dis, 84S (1973), pp. 53-59
[35.]
A.H.W. Assendelf.
Renal failure and hemolysis caused by rifampicin.
Tubercle, 67 (1986), pp. 234-235
[36.]
M.R. Holdiness.
A review of blood dyserasias induced by the antituberculosis drugs.
Tubercle, (1987), pp. 301-309
[37.]
J.R. Cohn, D.L. Fye, J.M. Sills, G.C. Francos.
Rifampicin-induced renal failure.
Tubercle, 66 (1985), pp. 289-293
[38.]
W.C. Chan, G.M. O’Mahoney, D.Y.C. Yu, R.Y.H. Yu.
Renal failure during intermittent rifampicin therapy.
Tubercle, 56 (1975), pp. 191-198
[39.]
M. Cochran, P.J. Moorhead, M. Platts.
Permanent renal damage with rifampicin.
Lancet, 1 (1975), pp. 1.428
[40.]
G. Acocella, R. Conti.
Interaction of rifampicin with other drugs.
Tubercle, 61 (1980), pp. 171-177
[41.]
D.E. Snider.
Pyridoxine supplementation during isoniazid therapy.
Tubercle, 61 (1980), pp. 191-196
[42.]
S. Devadatta, P.R.J. Gangadharam, R.H. Andrews, et al.
Peripheral neuritis due to isoniazid.
Bull World Hlth Org, 23 (1960), pp. 587-598
[43.]
R. McCune, K. Deuschle, W. McDermott.
Delayed appearance of isoniazid antagonism by pyridoxine in vivo.
Am Rev Tub Respir Dis, 76 (1957), pp. 1.100-1.105
[44.]
D.A. Bender, R. Russell-Jones.
Isoniazid-induced pellagra despite vitamin B6 supplementation.
Lancet, 2 (1979), pp. 1.125-1.126
[45.]
R. Rey, A. Espinar.
Normativa sobre el tratamiento de la enfermedad y la infección tuberculosa.
Recomendaciones SEPAR. Ed Doyma, (1987),
[46.]
Hong Kong tuberculosis treatment services/British Medical Research Council.
Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong.
Tubercle, 57 (1976), pp. 81-95
[47.]
P.J. Jenner, G.A. Ellard, W.G.L. Alian, D. Singh, D.J. Girling, A.J. Nunn.
Serum uric acid concentrations and arthralgia among patients treated with pyrazinamide-containing regimens in Hong Kong and Singapore.
Tubercle, 62 (1981), pp. 175-179
[48.]
P.A.L. Horsfall, J. Plummer, W.G.L. Alian, D.J. Girling, A.J. Nunn, W. Fox.
Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration.
Tubercle, 60 (1979), pp. 13-24
[49.]
J.M. Symonds.
Aminoglycoside ototoxicity.
J Antimicrobiol Chemoth, 4 (1978), pp. 199-201
[50.]
Antituberculosis regimens of chemotherapy.
Recommendations from the Committee on Treatment of the International Union Against Tuberculosis and Lung Diseases.
Bull Int Un Tuberc, 63 (1988), pp. 60-64
[51.]
A. Kerremans, L.H. Majoor.
Hypersensitivity to ethambutol.
Tubercle, 62 (1981), pp. 215-217
[52.]
Hong Kong Chest Service/British Medical Research Council.
Controlled trial of four twice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis.
Lancet, 1 (1981), pp. 171-174
[53.]
S.Z. Kalinoswki, T.W. Lloyd, E.N. Moyes.
Complications in the chemotherapy of tuberculosis.
Am Rev Respir Dis, 83 (1961), pp. 359-371
[54.]
W. Lester.
Treatment of drug-resistant tuberculosis.
Dis Mon april, (1971), pp. 3-43
[55.]
British Tuberculosis Association.
An investigation of the value of ethionamide with pyrazinamide or cycloserine in the treatment of chronic pulmonary tuberculosis.
Tubercle, 42 (1961), pp. 269-286
[56.]
American Thoracic Society.
Diagnostic and treatment of diseases caused for non-tuberculous mycobacteria.
Am Rev Respir Dis, 142 (1990), pp. 940-953
[57.]
American Thoracic Society.
Treatment of tuberculosis and other mycobacterial diseases.
Am Rev Respir Dis, 127 (1983), pp. 790-796
[58.]
F.J. Guerra.
Los neumólogos y la tuberculosis.
Enfermedades. del tórax, 33–1 (1984), pp. 47-62
[59.]
D.A. Mitchison.
Basic mechanisms of chemotherapy.
Chest, 76S (1979), pp. 771-781
[60.]
J.B. Bass.
Tuberculin test, preventive therapy and elimination of tuberculosis.
Am Rev Respir Dis, 141 (1990), pp. 812-813
[61.]
W.W. Stead.
Control of tuberculosis in institutions.
Chest, 76S (1979),
[62.]
American Thoracic Society.
Diagnostic standars and classification of tuberculosis.
Am Rev Respir Dis, 142 (1990), pp. 725-735
[63.]
P. March Ayuela.
La evolución de la tuberculosis en España: Situación actual. Dificultades y errores epidemiológicos.
Arch Bronconeumol, 23 (1987), pp. 181-191
[64.]
P. March Ayuela, S.I.D.A. Tuberculosis.
Situación en España.
Perspectivas. Rev Clin Esp, 186 (1990), pp. 365-368
[65.]
K.H. Hsu.
Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents.
JAMA, 251 (1984), pp. 1.283-1.285
[66.]
Centers for Disease Control/American Thoracic Society.
Treatment of tuberculosis and tuberculosis infection in adults and children.
Am Rev Respir Dis, 134 (1986), pp. 355-363
[67.]
Chemotherapy, management of tuberculosis in the United Kingdom: Recommendations of the Joint Tuberculosis Committee of the British Thoracic Society.
Thorax, 45 (1990), pp. 403-408
[68.]
R. Rey.
Conducta terapéutica en la tuberculosis pulmonar: enfermos de retratamiento.
Arch Bronconeumol, 15 (1979), pp. 88-91
[69.]
J. Crofton.
Fracaso del tratamiento de la tuberculosis pulmonar. Causas posibles y como evitarlas.
Bol Un Int Tuberc, 55 (1980), pp. 93-100
[70.]
J.A. Sbarbaro.
Compliance: inducements and enforcements.
Chest, 76S (1979), pp. 750-756
[71.]
D.L. Dudley.
Why patients don’t take pills.
Chest, 76S (1979), pp. 744-749
[72.]
Consenso Nacional para el Control de la Tuberculosis en España.
Med Clin, 98 (1992), pp. 24-31
Copyright © 1993. Sociedad Española de Neumología y Cirugía Torácica
